Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Mixed with IFA, IFA and IFN-alpha, IFA and IL-2, or IFA and GM-CSF for Patients with Digestive Cancer and Endocrine Organic Cancer (Phase I clinical study)

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2007
This article has no abstract
Epistemonikos ID: 7e8ba7067ab00ad830ba404e34c35471172de819
First added on: Apr 16, 2025